Preventive Effects of Alprostadil Against Contrast-Induced Nephropathy Inpatients With Renal Insufficiency Undergoing Percutaneous Coronary Intervention. (May 2018)
- Record Type:
- Journal Article
- Title:
- Preventive Effects of Alprostadil Against Contrast-Induced Nephropathy Inpatients With Renal Insufficiency Undergoing Percutaneous Coronary Intervention. (May 2018)
- Main Title:
- Preventive Effects of Alprostadil Against Contrast-Induced Nephropathy Inpatients With Renal Insufficiency Undergoing Percutaneous Coronary Intervention
- Authors:
- Yang, Shi-Cheng
Fu, Nai-Kuan
Zhang, Jing
Liang, Min
Cong, Hong-Liang
Lin, Wen-Hua
Tian, Feng-Shi
Lu, Cheng-Zhi
Sun, Ting-Ting
Zhang, Wen-Ya
Ma, Zhen-Hua - Abstract:
- We investigated the preventive effect of alprostadil on contrast-induced nephropathy (CIN) in patients with renal insufficiency undergoing percutaneous coronary intervention (PCI). A total of 300 patients with creatinine clearance (crCl) ≤60 mL/min undergoing PCI were randomly assigned to alprostadil or a control group. The primary end point was the incidence of CIN defined as an increase in serum creatinine (Scr) levels by ≥0.5 mg/dL or≥ 25% after administration of the contrast media within 72 hours. The secondary end points were (1) changes in Scr and crCl within 72 hours and (2) the incidence of major adverse events during hospitalization. The incidence of CIN was 2.7% (4/150) in the alprostadil group, and 8.7% (13/150) in the control group (χ 2 = 5.05, P = .043).There was no difference regarding the incidence of major adverse events during hospitalization between the alprostadil group and control groups (2.7% vs 4.0%, P = .750). Multivariate logistic regression analysis showed that alprostadil was an independent protective factor for CIN (odds ratio = 0.136, 95% confidence interval: 0.020-0.944, P = .044). Prophylactic administration of alprostadil may prevent CIN in patients with renal insufficiency undergoing PCI.
- Is Part Of:
- Angiology. Volume 69:Number 5(2018)
- Journal:
- Angiology
- Issue:
- Volume 69:Number 5(2018)
- Issue Display:
- Volume 69, Issue 5 (2018)
- Year:
- 2018
- Volume:
- 69
- Issue:
- 5
- Issue Sort Value:
- 2018-0069-0005-0000
- Page Start:
- 393
- Page End:
- 399
- Publication Date:
- 2018-05
- Subjects:
- alprostadil -- contrast agent -- contrast-induced nephropathy -- renal insufficiency -- percutaneous coronary intervention -- prevention
Blood-vessels -- Diseases -- Periodicals
Cardiovascular system -- Diseases -- Periodicals
616.13005 - Journal URLs:
- http://ang.sagepub.com ↗
http://firstsearch.oclc.org ↗
http://galenet.galegroup.com/servlet/HWRC?locID=lcml_main ↗
http://www.sagepublications.com/ ↗ - DOI:
- 10.1177/0003319717730942 ↗
- Languages:
- English
- ISSNs:
- 0003-3197
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 8202.xml